Education
About Us
Working with TipRanks
Follow Us
ValiRx plc (GB:VAL)
:VAL
VAL Stock Chart & Stats
Day’s Range― - ―
52-Week Range0.38p - 3.50p
Previous CloseN/A
Volume1.58M
Average Volume (3M)1.08M
Market Cap
£1.68M
Enterprise Value1.28M
Total Cash (Recent Filing)£809.15K
Total Debt (Recent Filing)£17.00K
Price to Earnings (P/E)―
Beta-0.08
Next Earnings
Sep 15, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding374,348,660
10 Day Avg. Volume1,484,024
30 Day Avg. Volume1,076,504
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)2.67
Price to Sales (P/S)0.00
P/FCF Ratio-6.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
ValiRx plc News
PremiumCompany Announcements
ValiRx Announces Post-Results Investor Webinar with CEO
PremiumCompany Announcements
ValiRx PLC Reports 2024 Financial Results and Strategic Restructuring
PremiumCompany Announcements
ValiRx and Omios Biologics Collaborate on Oncolytic Cancer Therapies
PremiumCompany Announcements
ValiRx plc Announces Significant Shareholder Voting Rights Change
PremiumCompany Announcements
ValiRx Extends Drug Repurposing Deal with Dominion Biotech
PremiumCompany Announcements
ValiRx Expands Cancer Therapeutics Through Strategic PartnershipsPremiumCompany Announcements
ValiRx Terminates LOI with TheoremRx, Focuses on Prostate Cancer Asset
PremiumCompany Announcements
ValiRx Announces Board Restructuring and New Advisory Board FormationOptions Prices
Currently, No data available
---
Ownership Overview
7.41% Insiders
―
Mutual Funds
― Other Institutional Investors
92.59% Public Companies and
Individual Investors
VAL FAQ
What was ValiRx plc’s price range in the past 12 months?
ValiRx plc lowest share price was 0.38p and its highest was 3.50p in the past 12 months.
What is ValiRx plc’s market cap?
ValiRx plc’s market cap is £1.68M.
When is ValiRx plc’s upcoming earnings report date?
ValiRx plc’s upcoming earnings report date is Sep 15, 2025 which is in 94 days.
How were ValiRx plc’s earnings last quarter?
ValiRx plc released its earnings results on Jun 06, 2025. The company reported -0.002p earnings per share for the quarter, missing the consensus estimate of N/A by -0.002p.
Is ValiRx plc overvalued?
According to Wall Street analysts ValiRx plc’s price is currently Overvalued.
Does ValiRx plc pay dividends?
ValiRx plc does not currently pay dividends.
What is ValiRx plc’s EPS estimate?
ValiRx plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ValiRx plc have?
ValiRx plc has 374,348,660 shares outstanding.
What happened to ValiRx plc’s price movement after its last earnings report?
ValiRx plc reported an EPS of -0.002p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -10%.
Which hedge fund is a major shareholder of ValiRx plc?
Currently, no hedge funds are holding shares in GB:VAL
Company Description
ValiRx plc
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a small molecule that has completed Phase I/II trials for the treatment of prostate cancer and other hormone associated solid tumours comprising breast and ovarian cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of women with endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19. ValiRx plc was incorporated in 2000 and is based in Hatfield, the United Kingdom.
Technical Analysis
Evgen Pharma
―
Nuformix Plc
―
Oxford BioDynamics
―
Cizzle Biotechnology Holdings PLC
―
Fusion Antibodies Plc
―